Skip to main content
SpringerLink
Log in

Pharmacogenomics, Pharmacoproteomics, and Pharmacometabolomics and Personalized Medicine: An Overview

  • Chapter
  • First Online:
Omics for Personalized Medicine

  • 2071 Accesses

Abstract

The mapping of the human genome has been an important milestone in understanding the interindividual differences in genetic predisposition to diseases and individuals’ responsiveness to drugs. These factors have now begun to revolutionize the clinical landscape with new therapeutic strategies defined as “personalized medicine.” Personalized medicine is believed to transform the traditional “one size fits all” model of medicine by applying individual gene-based information to better manage a patient’s disease or predisposition toward a disease and to tailor strategies for the prevention and treatment of diseases. In this context, recent explosion in the omics tools and technologies is believed to generate valuable pharmacogenomic, proteomic, and metabolic information of patients which would serve as potential accelerating factors for the development of personalized medicine. Personalized medicine has the ability to change the overall landscape of medicine from diagnosis and treatment to prevention. The success of personalized therapy in the future will depend on scientific advances in pharmacogenomics, proteomics, and metabolics and on a systems biology approach in the diagnosis and treatment of complex diseases. This chapter discusses the basic concepts and advancements in the fields of pharmacogenomics, pharmacoproteomics, and pharmacometabolomics and their applications in personalized medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Addona TA, Shi X et al (2011) A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol 29(7):635–643

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • An HJ, Froehlich JW et al (2009) Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr Opin Chem Biol 13(4):421–426

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Anderson NL (2010) The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56(2):177–185

    Article  CAS  PubMed  Google Scholar 

  • Awada A, Vandone AM et al (2012) Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Curr Opin Oncol 24(3):297–304

    Article  PubMed  Google Scholar 

  • Beck M, Schmidt A et al (2011) The quantitative proteome of a human cell line. Mol Syst Biol 7:549

    PubMed Central  PubMed  Google Scholar 

  • Bencharit S (2012) Progresses and challenges of omics studies and their impacts in personalized medicine. J Pharmacogenomics Pharmacoproteomics 3(1):e105

    Google Scholar 

  • Beverage JN, Sissung TM et al (2007) CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 96(9):2224–2231

    Article  CAS  PubMed  Google Scholar 

  • Bhartiya D, Kapoor S et al (2012) Conceptual approaches for lncRNA drug discovery and future strategies. Expert Opin Drug Discov 7(6):503–513

    Article  CAS  PubMed  Google Scholar 

  • Bhasker CR, Hardiman G (2010) Advances in pharmacogenomics technologies. Pharmacogenomics 11(4):481–485

    Article  CAS  PubMed  Google Scholar 

  • Blum HE (2011) Personalized medicine. Praxis 100(3):159–166

    Article  CAS  PubMed  Google Scholar 

  • Bochud M, Burnier M et al (2011) Top three pharmacogenomics and personalized medicine applications at the nexus of renal pathophysiology and cardiovascular medicine. Curr Pharmacogenomics Person Med 9(4):299–322

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Boja ES, Rodriguez H (2012) Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics 12(8):1093–1110

    Article  CAS  PubMed  Google Scholar 

  • Chan SY, White K et al (2012) Deciphering the molecular basis of human cardiovascular disease through network biology. Curr Opin Cardiol 27(3):202–209

    Article  PubMed Central  PubMed  Google Scholar 

  • Chen R, Mias GI et al (2012) Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148(6):1293–1307

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cho A, Normile D (2002) Nobel Prize in chemistry. Mastering macromolecules. Science 298(5593):527–528

    Article  PubMed  Google Scholar 

  • Chouchane L, Mamtani R et al (2011) Personalized medicine: a patient-centered paradigm. J Transl Med 9:206

    Article  PubMed Central  PubMed  Google Scholar 

  • Choudhary C, Kumar C et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942):834–840

    Article  CAS  PubMed  Google Scholar 

  • Clayton TA, Lindon JC et al (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087):1073–1077

    Article  CAS  PubMed  Google Scholar 

  • Costa FF (2009) Non-coding RNAs and new opportunities for the private sector. Drug Discov Today 14(9–10):446–452

    Article  CAS  PubMed  Google Scholar 

  • Davis JC, Furstenthal L et al (2009) The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov 8(4):279–286

    Article  CAS  PubMed  Google Scholar 

  • Donnelly LA, Doney AS et al (2011) Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 89(2):210–216

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Downard KM (2007) Historical account: Francis William Aston: the man behind the mass spectrograph. Eur J Mass Spectrom (Chichester, Eng) 13(3):177–190

    Article  CAS  Google Scholar 

  • Farooqi AA, Rana A et al (2012) NutriTRAILomics in prostate cancer: time to have two strings to one’s bow. Mol Biol Rep 39(4):4909–4914

    Article  CAS  PubMed  Google Scholar 

  • Fenn JB, Mann M et al (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science 246(4926):64–71

    Article  CAS  PubMed  Google Scholar 

  • Grimsrud PA, Swaney DL et al (2010) Phosphoproteomics for the masses. ACS Chem Biol 5(1):105–119

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gucek M, Murphy E (2010) What can we learn about cardioprotection from the cardiac mitochondrial proteome? Cardiovasc Res 88(2):211–218

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hall AM, Wilkins MR (2005) Warfarin: a case history in pharmacogenetics. Heart 91(5):563–564

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hardiman G (2008) Applications of microarrays and biochips in pharmacogenomics. Methods Mol Biol 448:21–30

    Article  CAS  PubMed  Google Scholar 

  • Hardman M, Makarov AA (2003) Interfacing the orbitrap mass analyzer to an electrospray ion source. Anal Chem 75(7):1699–1705

    Article  CAS  PubMed  Google Scholar 

  • Hippocrates C (1993) The sources of medical ethics: Hippocrates and his disciples. Rev Infirm 43(8):12–14

    CAS  PubMed  Google Scholar 

  • Hochholzer W, Morrow DA et al (2010) Novel biomarkers in cardiovascular disease: update 2010. Am Heart J 160(4):583–594

    Article  CAS  PubMed  Google Scholar 

  • Hong KW, Oh B (2010) Overview of personalized medicine in the disease genomic era. BMB Rep 43(10):643–648

    Article  CAS  PubMed  Google Scholar 

  • Huttlin EL, Jedrychowski MP et al (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143(7):1174–1189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jaffe AS (2012) Troponin – past, present, and future. Curr Probl Cardiol 37(6):209–228

    Article  PubMed  Google Scholar 

  • Jain KK (2004) Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 5(3):331–336

    Article  CAS  PubMed  Google Scholar 

  • Joffe HV, Xu R et al (2004) Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 91(6):1123–1128

    CAS  PubMed  Google Scholar 

  • Kaddurah-Daouk R, Kristal BS et al (2008) Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48:653–683

    Article  CAS  PubMed  Google Scholar 

  • Kim SC, Sprung R et al (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23(4):607–618

    Article  CAS  PubMed  Google Scholar 

  • Klawitter J, Haschke M et al (2010) Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol 70(2):241–251

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Korman A, Oh A et al (2012) Statistical methods in metabolomics. Methods Mol Biol 856:381–413

    Article  PubMed  Google Scholar 

  • Kuhn E, Whiteaker JR et al (2012) Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics 11(6):M111 013854

    PubMed Central  PubMed  Google Scholar 

  • Longo R, D’Andrea M et al (2010) Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab. Expert Opin Investig Drugs 19(Suppl 1):S41–S50

    Article  CAS  PubMed  Google Scholar 

  • Loscalzo J (2011) Systems biology and personalized medicine: a network approach to human disease. Proc Am Thorac Soc 8(2):196–198

    Article  PubMed  Google Scholar 

  • Ma JD, Lee KC et al (2012) Clinical application of pharmacogenomics. J Pharm Pract 25(4):417–427

    Article  PubMed  Google Scholar 

  • Macek B, Mann M et al (2009) Global and site-specific quantitative phosphoproteomics: principles and applications. Annu Rev Pharmacol Toxicol 49:199–221

    Article  CAS  PubMed  Google Scholar 

  • Madian AG, Wheeler HE et al (2012) Relating human genetic variation to variation in drug responses. Trends Genet 28(10):487–495

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Malki K, Campbell J et al (2012) Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Proteomics 12(14):2355–2365

    Article  CAS  PubMed  Google Scholar 

  • Manavalan A, Feng L et al (2012) New insights into the brain protein metabolism of Gastrodia elata-treated rats by quantitative proteomics. J Proteomics 75(8):2468–2479

    Article  CAS  PubMed  Google Scholar 

  • Mangravite LM, Wilke RA et al (2008) Pharmacogenomics of statin response. Curr Opin Mol Ther 10(6):555–561

    CAS  PubMed  Google Scholar 

  • Matkovich SJ, Zhang Y et al (2010) Deep mRNA sequencing for in vivo functional analysis of cardiac transcriptional regulators: application to Galphaq. Circ Res 106(9):1459–1467

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McGraw J, Waller D (2012) Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 8(3):371–382

    Article  CAS  PubMed  Google Scholar 

  • Mehta R, Jain RK et al (2011) Personalized medicine: the road ahead. Clin Breast Cancer 11(1):20–26

    Article  CAS  PubMed  Google Scholar 

  • Mini E, Nobili S (2009) Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 6(1):17–24

    PubMed Central  PubMed  Google Scholar 

  • Mocellin S, Shrager J et al (2010) Targeted Therapy Database (TTD): a model to match patient’s molecular profile with current knowledge on cancer biology. PLoS One 5(8):e11965

    Article  PubMed Central  PubMed  Google Scholar 

  • Murphy E, Kohr M et al (2012) S-nitrosylation: a radical way to protect the heart. J Mol Cell Cardiol 52(3):568–577

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nagaraj N, Wisniewski JR et al (2011) Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol 7:548

    PubMed Central  PubMed  Google Scholar 

  • Newman WG (2012) Pharmacogenetics: transforming clinical medicine. J R Coll Physicians Edinb 42(3):244–247

    Article  CAS  PubMed  Google Scholar 

  • Nicholson JK, Wilson ID et al (2011) Pharmacometabonomics as an effector for personalized medicine. Pharma-cogenomics 12(1):103–111

    Article  CAS  Google Scholar 

  • Nielsen FC, Borregaard N (2009) Pharmacogenetics and tailored drug therapy. Ugeskr Laeger 171(10):790–794

    PubMed  Google Scholar 

  • Nita-Lazar A (2011) Quantitative analysis of phosphorylation-based protein signaling networks in the immune system by mass spectrometry. Wiley Interdiscip Rev Syst Biol Med 3(3):368–376

    Article  CAS  PubMed  Google Scholar 

  • Pan C, Olsen JV et al (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8(12):2796–2808

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Panareo S, Rossi R et al (2011) A practical method for the estimation of therapeutic activity in the treatment of Graves’ hyperthyroidism. Q J Nucl Med Mol Imaging 55(5):576–585

    CAS  PubMed  Google Scholar 

  • Pareek CS, Smoczynski R et al (2011) Sequencing technologies and genome sequencing. J Appl Genet 52(4):413–435

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Patti GJ, Yanes O et al (2012) Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13(4):263–269

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Paulo JA, Kadiyala V et al (2012) Mass spectrometry-based proteomics for translational research: a technical overview. Yale J Biol Med 85(1):59–73

    CAS  PubMed Central  PubMed  Google Scholar 

  • Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 9(6):555–566

    Article  CAS  PubMed  Google Scholar 

  • Prensner JR, Rubin MA et al (2012) Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4(127):127rv123

    Google Scholar 

  • PubMed from http://www.ncbi.nlm.nih.gov/pubmed/

  • Qattan M, Demonacos C et al (2012) Roadmap to personalized medicine. Croat Med J 53(4):294–297

    Article  PubMed Central  PubMed  Google Scholar 

  • Ram PT, Mendelsohn J et al (2012) Bioinformatics and systems biology. Mol Oncol 6(2):147–154

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rio J, Comabella M et al (2009) Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 5(10):553–560

    Article  CAS  PubMed  Google Scholar 

  • Roden DM, Altman RB et al (2006) Pharmacogenomics: challenges and opportunities. Ann Intern Med 145(10):749–757

    Article  PubMed  Google Scholar 

  • Roederer MW, McLeod HL (2010) Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics 11(5):633–636

    Article  PubMed  Google Scholar 

  • Sadee W (2011) Genomics and personalized medicine. Int J Pharm 415(1–2):2–4

    Article  CAS  PubMed  Google Scholar 

  • Serkova NJ, Brown MS (2012) Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers. Bioanalysis 4(3):321–341

    Article  CAS  PubMed  Google Scholar 

  • Shi Y, Xu P et al (2011) Ubiquitinated proteome: ready for global? Mol Cell Proteomics 10(5):R110 006882

    PubMed Central  PubMed  Google Scholar 

  • Sreekumar A, Poisson LM et al (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231):910–914

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Stastna M, Van Eyk JE (2012) Secreted proteins as a fundamental source for biomarker discovery. Proteomics 12(4–5):722–735

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sudhindra A, Ochoa R et al (2011) Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. Clin Lung Cancer 12(6):360–368

    Article  CAS  PubMed  Google Scholar 

  • Superko HR, Momary KM et al (2012) Statins personalized. Med Clin North Am 96(1):123–139

    Article  CAS  PubMed  Google Scholar 

  • van Rooij T, Wilson DM et al (2012) Personalized medicine policy challenges: measuring clinical utility at point of care. Expert Rev Pharmacoecon Outcomes Res 12(3):289–295

    Article  PubMed  Google Scholar 

  • Vermeire S, Van Assche G et al (2010) Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 16(21):2609–2615

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Vertegaal AC (2011) Uncovering ubiquitin and ubiquitin-like signaling networks. Chem Rev 111(12):7923–7940

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Whirl-Carrillo M, McDonagh EM et al (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92(4):414–417

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Winnike JH, Li Z et al (2010) Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 88(1):45–51

    Article  CAS  PubMed  Google Scholar 

  • Witzmann FA, Grant RA (2003) Pharmacoproteomics in drug development. Pharmacogenomics J 3(2):69–76

    Article  CAS  PubMed  Google Scholar 

  • Yu LR (2011) Pharmacoproteomics and toxicoproteomics: the field of dreams. J Proteomics 74(12):2549–2553

    Article  CAS  PubMed  Google Scholar 

  • Zhang A, Sun H et al (2012a) Modern analytical techniques in metabolomics analysis. Analyst 137(2):293–300

    Article  CAS  PubMed  Google Scholar 

  • Zhang A, Sun H et al (2012b) Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal Bioanal Chem 404(4):1239–1245

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the support from the Intramural Research Program of NHLBI/NIH.

Author information

Authors and Affiliations

  1. Division of Geriatrics & Clinical Gerontology, National Institute of Aging, NIH, Bethesda, MD, 20892, USA

    Nalini Raghavachari

  2. DNA Sequencing and Genomics Core Facility – Genetics and Developmental Biology Center, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA

    Nalini Raghavachari

  3. Proteomics Core Facility – Systems Biology Center, National Heart Lung and Blood Institute, National Institutes of Health, Bldg 10, Center Drive, R, 8C 103, Bethesda, MD, 20892, USA

    Marjan Gucek

Authors
  1. Nalini Raghavachari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marjan Gucek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nalini Raghavachari .

Editor information

Editors and Affiliations

  1. Centre for Genomics & Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, West Bengal, India

    Debmalya Barh

  2. Institute of Life Sciences, B.V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad University, Ahmedabad, Gujarat, India

    Dipali Dhawan

  3. Policy Centre for Biomedical Research, Translational Health Science and Technology Institute (Department of Biotechnology Institute, Government of India), Office @ National Institute of Immunology, New Delhi, India

    Nirmal Kumar Ganguly

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer India

About this chapter

Cite this chapter

Raghavachari, N., Gucek, M. (2013). Pharmacogenomics, Pharmacoproteomics, and Pharmacometabolomics and Personalized Medicine: An Overview. In: Barh, D., Dhawan, D., Ganguly, N. (eds) Omics for Personalized Medicine. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1184-6_1

Download citation

Publish with us

Policies and ethics

Search

Navigation